BRISTOL-MYERS SQUIBB COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 44.01 USD | -0.23% |
|
-2.07% | -14.23% |
| May. 16 | Everlasting momentum |  |
| May. 16 | Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma | DJ |
Presentation Operator MessageOperator (Operator)Good day, and welcome to Bristol-Myers Squibb'...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
2024-07-26
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
44.03
USD
Average target price
53.19
USD
Spread / Average Target
+20.81%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -14.23% | 89.25B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Transcript : Bristol-Myers Squibb Company - Shareholder/Analyst Call
